SCHEMBL6709685

SCHEMBL6709685

Nc1ccc(N2CCN(C(=O)c3ccc(Cl)s3)CC2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.75
ALDH1A1 P00352 7/20 0.61
HPGD P15428 2/20 0.61
LMNA P02545 7/20 0.61
ALOX12 P18054 3/20 0.61
GAA P10253 3/20 0.61
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
GFER P55789 2/20 0.54
CASP6 P55212 1/20 0.54
HTT P42858 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709683 0.86 MAPT (0.71) MAPTALDH1A1HPGDLMNAALOX12
SCHEMBL6712582 0.76 MAPT (1.00) MAPTALDH1A1LMNAALOX12GAA
SCHEMBL20460413 0.76 HPGD (0.96) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL9321490 0.75 LMNA (0.74) MAPTALDH1A1LMNACA12CA1
SCHEMBL13437944 0.74 HRH3 (0.58) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL28806386 0.73 GFER (0.73) MAPTALDH1A1HPGDLMNAALOX12
SCHEMBL30876047 0.73 HPGD (0.73) MAPTALDH1A1HPGDLMNACA12
SCHEMBL23928684 0.73 LMNA (0.63) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL23244266 0.72 MAPT (0.59) MAPTALDH1A1HPGDLMNACA12
SCHEMBL29576369 0.72 MAPT (0.59) MAPTALDH1A1HPGDLMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same PIERRE FABRE MEDICAMENT (FR) 2004-05-13 US disclosed
EP-1324999-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2003-07-09 EP disclosed
WO-2002030927-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same CBR3, CBR1, HCCS MAPT 4753/4885ALDH1A1 3031/4885HPGD 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.